Clinical pharmacokinetics of mifepristone.

abstract：BACKGROUND:Recombinant methionyl human leptin (r-metHuLeptin) has demonstrated efficacy in improving hormonal and metabolic parameters in leptin-deficient states, and it has been suggested that leptin replacement may reverse metabolic adaptations during weight loss interventions. The pharmacokinetics of subcutaneously ...

journal_title：Clinical pharmacokinetics

authors： Chan JL,Wong SL,Mantzoros CS

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Therapeutic hypothermia can influence the pharmacokinetics and pharmacodynamics of drugs, the discipline which is called thermopharmacology. We studied the effect of therapeutic hypothermia on the pharmacokinetics of phenobarbital in asphyxiated neonates, and the clinical efficacy and the effe...

journal_title：Clinical pharmacokinetics

authors： van den Broek MP,Groenendaal F,Toet MC,van Straaten HL,van Hasselt JG,Huitema AD,de Vries LS,Egberts AC,Rademaker CM

更新日期：2012-10-01 00:00:00

abstract：:Rational pharmacotherapy is dependent upon an understanding of the clinical pharmacokinetic and pharmacodynamic properties of the drugs employed. Although the available data on drug biodisposition and action in the neonate have increased considerably in the last few years, pharmacokinetic-pharmacodynamic interactions ...

journal_title：Clinical pharmacokinetics

authors： Besunder JB,Reed MD,Blumer JL

更新日期：1988-04-01 00:00:00

abstract：:Sulphonylureas have remained the mainstay of oral therapy for type 2 (non-insulin-dependent) diabetes mellitus (NIDDM). They stimulate insulin release from pancreatic beta cells. Pharmacokinetic differences between the various sulphonylureas are of clinical importance in terms of the time to onset of action, timing of...

journal_title：Clinical pharmacokinetics

authors： Melander A,Donnelly R,Rydberg T

更新日期：1998-03-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Imeglimin (IMEG) is the first in a novel class of oral glucose-lowering agents with a unique mechanism of action targeting mitochondrial bioenergetics. We assessed whether repeated co-administration of IMEG and either metformin (MET) or sitagliptin (SITA) would influence the pharmacokinetics o...

journal_title：Clinical pharmacokinetics

authors： Fouqueray P,Perrimond-Dauchy S,Bolze S

更新日期：2020-10-01 00:00:00

abstract：:Acute coronary syndromes (ACS) remain life-threatening disorders associated with high morbidity and mortality, despite advances in treatment over the last decade. Adenosine diphosphate-induced platelet activation via P2Y(12) receptors plays a pivotal role in the pathophysiology of ACS. The current standard of treatmen...

journal_title：Clinical pharmacokinetics

authors： Teng R

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND:Tildrakizumab is an anti-interleukin-23p19 monoclonal antibody recently approved for the treatment of chronic plaque psoriasis. METHODS:This analysis characterizes the population pharmacokinetics of subcutaneous tildrakizumab and identifies covariates influencing exposure in 2098 healthy volunteers and subj...

journal_title：Clinical pharmacokinetics

authors： Jauslin P,Kulkarni P,Li H,Vatakuti S,Hussain A,Wenning L,Kerbusch T

更新日期：2019-08-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer. The aim of this phase II, crossover, bioequivalence study was to compare the pharmacokinetics (primary objective) and tolerability (secondary objective) of tegafur-uracil (UFT) given as three daily doses (tid, r...

journal_title：Clinical pharmacokinetics

authors： Etienne-Grimaldi MC,François E,Cardot JM,Renée N,Douillard JY,Gamelin E,Bennouna J,Château Y,Milano G

更新日期：2007-01-01 00:00:00

abstract：:The critically ill patient occupies an increasing amount of time and bed space in modern hospital practice, and also commands increasing expenditure. Drug therapy in these patients has, in the past, been based on data derived from healthy volunteers, fit anaesthetised patients undergoing minor operative procedures, or...

journal_title：Clinical pharmacokinetics

authors： Bodenham A,Shelly MP,Park GR

更新日期：1988-06-01 00:00:00

abstract：:Bioequivalence of drug formulations plays an important role in drug development. Recently, the Biopharmaceutical Classification System (BCS) has been implemented for the purpose of waiving bioequivalence studies on the basis of the solubility and gastrointestinal permeability of drug substance. Using the rationale of ...

journal_title：Clinical pharmacokinetics

authors： Faassen F,Vromans H

更新日期：2004-01-01 00:00:00

abstract：OBJECTIVE:The aim of this study was to characterize the relationship between morphine plasma concentration and repeated time to postoperative remedication events in children undergoing cardiac surgery. METHODS:Data from our previously published study of morphine pharmacokinetics were utilized in this pharmacodynamic s...

journal_title：Clinical pharmacokinetics

authors： Elkomy MH,Drover DR,Galinkin JL,Hammer GB,Glotzbach KL

更新日期：2016-10-01 00:00:00

abstract：:It should be recognized that children are not small adults, hence dosing in children should not be a 'small adult dose'. A mean population dose in all age groups is just an average dose and not necessarily the best or the correct dose for a given patient. The dose of a drug varies from patient to patient and individua...

journal_title：Clinical pharmacokinetics

authors： Mahmood I

更新日期：2014-04-01 00:00:00

abstract：:This review examines the literature on drug interactions with omeprazole. Different mechanisms have been proposed as potential causes for such interactions. First, the absorption of some drugs might be altered due to the decreased intragastric acidity resulting from omeprazole treatment. There was no effect of omepraz...

journal_title：Clinical pharmacokinetics

authors： Andersson T

更新日期：1991-09-01 00:00:00

abstract：:Despite contributing significantly to the burden of global disease, the translation of new treatment strategies for diseases of the central nervous system (CNS) from animals to humans remains challenging, with a high attrition rate in the development of CNS drugs. The failure of clinical trials for CNS therapies can b...

journal_title：Clinical pharmacokinetics

authors： Srinivas N,Maffuid K,Kashuba ADM

更新日期：2018-09-01 00:00:00

abstract：:Protein binding of antibacterials in plasma and tissues has long been considered a component of their pharmacokinetic parameters, playing a potential role in distribution, excretion and therapeutic effectiveness. Since the beginning of the 'antibacterial era', this factor has been extensively analysed for all antibact...

journal_title：Clinical pharmacokinetics

authors： Bergogne-Bérézin E

更新日期：2002-01-01 00:00:00

abstract：:Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK9 to reduce LDL-C. Evolocumab exhibits nonlinear kine...

journal_title：Clinical pharmacokinetics

authors： Kasichayanula S,Grover A,Emery MG,Gibbs MA,Somaratne R,Wasserman SM,Gibbs JP

更新日期：2018-07-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Clearance is an important pharmacokinetic concept for scaling dosage, understanding the risks of drug-drug interactions and environmental risk assessment in children. Accurate clearance scaling to children requires prior knowledge of adult clearance mechanisms and the age-dependence of physiolo...

journal_title：Clinical pharmacokinetics

authors： Edginton AN,Schmitt W,Voith B,Willmann S

更新日期：2006-01-01 00:00:00

abstract：:The ability of a new multiple-dose non-linear regression analysis program to predict steady-state aminoglycoside peak and trough serum concentrations was evaluated. 30 patients receiving either amikacin (7), gentamicin (10) or tobramycin (13) were studied. A standard method of prediction which requires the collection ...

journal_title：Clinical pharmacokinetics

authors： Koup JR,Killen T,Bauer LA

更新日期：1983-09-01 00:00:00

abstract：OBJECTIVE:To assess the differences between patients with hepatic insufficiency and healthy subjects with regard to the pharmacokinetics, cardiac safety and overall safety of ebastine and its active metabolite carebastine. DESIGN:Open-label parallel-group study. PARTICIPANTS:24 patients with varying degrees of hepati...

journal_title：Clinical pharmacokinetics

authors： Lasseter KC,Dilzer SC,Vargas R,Waldman S,Noveck RJ

更新日期：2004-01-01 00:00:00

abstract：:Creatine is a nonessential dietary component that, when supplemented in the diet, has shown physiological benefits in athletes, in animal-based models of disease and in patients with various muscle, neurological and neuromuscular disease. The clinical relevance of creatine supplementation is based primarily on its rol...

journal_title：Clinical pharmacokinetics

authors： Persky AM,Brazeau GA,Hochhaus G

更新日期：2003-01-01 00:00:00

abstract：:Vedolizumab is a humanized anti-α4β7 integrin monoclonal antibody that selectively blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α4β7-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) interaction. Approved for treating patients with moderately to severely active ulcerative colitis (...

journal_title：Clinical pharmacokinetics

authors： Rosario M,Dirks NL,Milch C,Parikh A,Bargfrede M,Wyant T,Fedyk E,Fox I

更新日期：2017-11-01 00:00:00

abstract：:There are many pathological changes in patients with cystic fibrosis (CF) which can lead to alterations in drug disposition. Although, in patients with CF, the extent of drug absorption varies widely and the rate of absorption is slower, bioavailability is not altered. Plasma protein binding for the majority of drugs ...

journal_title：Clinical pharmacokinetics

authors： Rey E,Tréluyer JM,Pons G

更新日期：1998-10-01 00:00:00

abstract：:The US Food and Drug Administration (FDA) draft guidance for industry on drug interaction studies recommends, but does not mandate, that both cigarette smokers and non-smokers can be used to study drug metabolism in clinical trials, and that important results related to smoking should be included in drug labelling to ...

journal_title：Clinical pharmacokinetics

authors： Li H,Shi Q

更新日期：2015-05-01 00:00:00

abstract：OBJECTIVE:The objective of this analysis was to simulate the performance of oral triptan formulations with varying absorption characteristics and their impact on the onset and magnitude of the antimigraine effect using a Markov model for migraine attacks. ANALYSIS:Sumatriptan pharmacokinetic data were obtained from cl...

journal_title：Clinical pharmacokinetics

authors： Maas HJ,Spruit MA,Danhof M,Della Pasqua OE

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Because of the vulnerability and frailty of elderly adults, clinical drug development has traditionally been biased towards young and middle-aged adults. Recent efforts have begun to incorporate data from paediatric investigations. Nevertheless, the elderly often remain underrepresented in clinical trials, e...

journal_title：Clinical pharmacokinetics

authors： Schlender JF,Meyer M,Thelen K,Krauss M,Willmann S,Eissing T,Jaehde U

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Buprenorphine has been shown to be effective in treating infants with neonatal opioid withdrawal syndrome. However, an evidence-based buprenorphine dosing strategy has not been established in the treatment of neonatal opioid withdrawal syndrome because of a lack of exposure-response data. The a...

journal_title：Clinical pharmacokinetics

authors： Mizuno T,McPhail BT,Kamatkar S,Wexelblatt S,Ward L,Christians U,Akinbi HT,Vinks AA

更新日期：2020-09-17 00:00:00

abstract：:Fluorouracil is used clinically against various solid tumours. Both fluorouracil toxicity and pharmacokinetics vary highly within and between individuals. The reasons why doses are not individualised routinely are difficulties in defining, predicting and achieving an optimal fluorouracil exposure or dose because of a ...

journal_title：Clinical pharmacokinetics

authors： Ploylearmsaeng SA,Fuhr U,Jetter A

更新日期：2006-01-01 00:00:00

abstract：:Interleukins and tumour necrosis factor (TNF) are a complex group of proteins and glycoproteins able to exert pleiotropic effects with respect to a number of different target cells. In physiological conditions, they are induced and released in basal amounts only in restricted microenvironments where they have paracrin...

journal_title：Clinical pharmacokinetics

authors： Bocci V

更新日期：1991-10-01 00:00:00

abstract：:Following administration of equivalent oral doses (30mg) of either prednisone or prednisolone to 5 patients with chronic active liver disease who had failed to respond to therapy, 5 patients with chronic active liver disease in remission induced by prednisone, and 7 healthy volunteers, corticosteroid concentrations we...

journal_title：Clinical pharmacokinetics

authors： Uribe M,Summerskill WH,Go VL

更新日期：1982-09-01 00:00:00

abstract：:Low-molecular-weight heparins are anticoagulants used in the treatment of thrombosis. They have effectiveness and safety profiles similar to those of unfractionated heparin but are considered an attractive alternative because of their predictable pharmacokinetic characteristics. In this article, we demonstrate the nee...

journal_title：Clinical pharmacokinetics

authors： Al-Sallami HS,Barras MA,Green B,Duffull SB

更新日期：2010-09-01 00:00:00